URACHAL ADENOCARCINOMA
Clinical trials for URACHAL ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new URACHAL ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for URACHAL ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for rare cancers: Triple-Drug attack shows promise
Disease control Recruiting nowThis phase II trial is testing whether a combination of three drugs—cabozantinib, nivolumab, and ipilimumab—can shrink or slow the growth of rare genitourinary cancers that have spread. About 314 adults with these uncommon tumors will receive the drugs. The goal is to see if the …
Matched conditions: URACHAL ADENOCARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Can a targeted antibody-drug combo tackle rare bladder cancers?
Disease control Recruiting nowThis phase II trial is testing whether combining enfortumab vedotin—a drug that delivers a cancer-killing agent directly to tumor cells—with the immunotherapy pembrolizumab can shrink tumors in people with locally advanced or metastatic bladder cancer of variant histology. These …
Matched conditions: URACHAL ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Emory University • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC